Anacor Pharmaceuticals

Organization Address
1020 E Meadow Cir
Palo Alto, CA 94303-4230

Organization Phone
(650) 543-7500



Organization Description
Anacor is a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule therapeutics derived from its novel boron chemistry platform. We have discovered, synthesized and developed eight product candidates currently in development. Our two lead product candidates are topically administered dermatologic compounds-tavaborole (formerly AN2690), a topical antifungal for the treatment of onychomycosis, and AN2728 a topical anti-inflammatory for the treatment of atopic dermatitis and psoriasis. In addition to our two lead programs, we have discovered three, other wholly-owned clinical product candidates ? AN2718 and AN2898, which are backup compounds to tavaborole and AN2728, respectively, and AN3365 (formerly known as GSK2251052, or GSK ?052), a systemic antibiotic for the treatment of infections caused by Gram-negative bacteria, which previously was licensed to GlaxoSmithKline LLC, or GSK. We have discovered three other compounds that we have out-licensed for further development ? two compounds for the treatment of animal health indications that are licensed to Eli Lilly and Company and AN5568, also referred to as SCYX-7158, for human African trypanosomiasis (HAT, or sleeping sickness), which is licensed to Drugs for Neglected Diseases initiative, or DNDi. In addition, we have a pipeline of internally developed topical and systemic boron- based compounds in development.

Clinical Development Stage
Phase III